CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease.  In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

Biotechnology

CiVi Biopharma

Shal Jacobovitz

Christa-Lynn Vampola

Allison Widlitz

Wade Benton

Kevin Christal

Chuck Shear

Henrik Ørum

Leadership Team

Teams at CiVi Biopharma

Leadership Team